helsinn therapeutics (u.s.), inc.

1140 us highway 22, ste. 101
bridgewater, new jersey 08807

NYS Entity Status
ACTIVE

NYS Filing Date
NOVEMBER 12, 2013

NYS DOS ID#
4485134

County
NEW YORK

Jurisdiction
DELAWARE

Registered Agent
NONE

NYS Entity Type
FOREIGN BUSINESS CORPORATION

Name History
2013 - HELSINN THERAPEUTICS (U.S.), INC.









Buffer



submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • AROUND THE WEB

  • “It’s Shame On Us If We Blow It”: Highlights From NY Seizes the Momentum
    By Ben Fidler - Wednesday Jun 7, 2017

    Mike Foley, a drug industry veteran and director of the Tri-Institutional Therapeutics Discovery Institute, has a pointed message for the New York life sciences industry: Don’t waste the moment. Changing the course of New York biotech has been a saga that dates back to the 1990s, and as Xconomy has detailed, progress has been made […]

    Source: Xconomy New York
  • United Therapeutics in Settlement Talks With Justice Department
    Thursday Jul 27, 2017

    United Therapeutics has set aside $210 million for a possible settlement of a U.S. Justice Department investigation of whether the company’s contributions to patient-assistance charity groups violate federal laws against kickbacks and false claims.

    Source: The Wall Street Journal: U.S. Business
  • For Parkinson’s, Two New Drugs Coming As Prevail Gets Started in NY
    By Ben Fidler - Wednesday Aug 9, 2017

    A drug that actually slows or reverses the brain damage inflicted by Parkinson’s disease, rather than just alleviates its often debilitating symptoms, remains elusive. But Prevail Therapeutics, a startup just launched in New York, has become the latest to try. This morning, the Silverstein Foundation, a nonprofit organization formed by OrbiMed partner Jonathan Silverstein, announced […]

    Source: Xconomy New York
  • Insurers Battle Families Over Costly Drug for Fatal Disease
    By KATIE THOMAS - Thursday Jun 22, 2017

    The case of Exondys 51 poses emotionally charged issues for families of young boys with a rare illness, who are fighting companies to get coverage for an expensive drug approved on a lower bar of proof.

    Source: NYT > Home Page
helsinn therapeutics us inc bridgewater ny